Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Why Is HemoGenyx Pharmaceuticals Among Today's Most Watched UK Biotech Stocks?

• LSE:HEMO gained 4.55% on 25 June 2026, making it one of the strongest-performing healthcare stocks on the FTSE AIM Index.

Ankur Sharma | 25 June 2026

UK Small-Cap Healthcare and Clean Energy Companies Attract Fresh Buying

• LSE:CINH gained 5.26% on 25 June 2026, emerging as one of the strongest performers on the FTSE AIM market.

Ankur Sharma | 25 June 2026

Is AstraZeneca's Drug Pipeline Strong Enough for Future Growth?

Explore AstraZeneca PLC’s growth drivers, business strengths, future catalysts, valuation perspective, key risks, technical levels, and frequently asked questions for investors.

Ishan Mudgal | 25 June 2026

Can Tissue Regenix Group plc Benefit from Rising Demand in Wound Care?

Explore Tissue Regenix Group plc with insights on key growth drivers, catalysts, risks, valuation outlook, technical levels, and regenerative medicine industry prospects.

Ishan Mudgal | 25 June 2026

Is Smith & Nephew Becoming a Major FTSE 100 Recovery Story?

Smith & Nephew was among the stronger FTSE 100 performers as investors increased exposure to healthcare companies offering defensive growth characteristics and global diversification.

Ankur Sharma | 25 June 2026

Could LSE:AZN - AstraZeneca PLC Be Reinforcing Its Position as a Global Healthcare Powerhouse

AstraZeneca emerged as one of the strongest-performing FTSE 100 healthcare stocks as investors sought stability, earnings visibility and long-term growth opportunities amid increasingly complex global market conditions.

Ankur Sharma | 25 June 2026

Is Haleon Becoming One of the Strongest FTSE 100 Defensive Growth Stories?

• Investors rotated into defensive healthcare names amid ongoing macroeconomic uncertainty.

Ankur Sharma | 25 June 2026

Are Biotech Risks Highlighted In Thalia Therapeutics Results?

Biotech companies occupy a distinctive position in the market. Rather than being judged primarily on near-term revenue, drug developers are often assessed on the progress of their pipeline, the milestones they reach and the way they fund their activities. This means a results update …

Ankur Sharma | 24 June 2026

Is ValiRx Entering a Critical Phase Ahead of Its Results Update?

Operating in oncology drug development, Valirx sits in a corner of the market known for both ambition and uncertainty. The forthcoming results give investors a moment to reassess the company against the demanding backdrop of clinical research.

Ankur Sharma | 24 June 2026

Why Is CellbXhealth Attracting Attention Ahead of Results?

This article takes a measured look at CellbXhealth ahead of its final results. Rather than predicting outcomes or assigning a value to the shares, the aim here is to set out the kinds of themes that market participants commonly consider around a reporting event. …

Ankur Sharma | 24 June 2026
Support

Hi! How can we help you today?

Loading…